Rockwell Medical
View On Demand

Rockwell Medical Submits IND To FDA For Home Infusion Therapy

About the Event

Rockwell Medical is a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management. The company recently submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration for home infusion therapy.

Their IND application with the FDA was submitted in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate, designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting. This increases access to treatment helping the company improve outcomes for patients around the world.

Join our webinar as Dr. Russell Ellison, Rockwell Medical President & CEO, shares the company’s latest news and how it’s moving forward to take advantage of the big opportunity in home infusion therapy for anemia.

View On-Demand Event


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.